CIA BRASILEIRA DE DIS- ADR (CBD)
US20440T3005 - ADR
Overall CBD gets a fundamental rating of 2 out of 10. We evaluated CBD against 41 industry peers in the Consumer Staples Distribution & Retail industry. CBD has a bad profitability rating. Also its financial health evaluation is rather negative. CBD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CBD has reported negative net income.
In the past year CBD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CBD reported negative net income in multiple years.
CBD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
CBD's Return On Assets of -10.30% is on the low side compared to the rest of the industry. CBD is outperformed by 78.05% of its industry peers.
Looking at the Return On Equity, with a value of -48.12%, CBD is doing worse than 80.49% of the companies in the same industry.
The Return On Invested Capital of CBD (0.48%) is worse than 70.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.3% | ||
| ROE | -48.12% | ||
| ROIC | 0.48% |
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of CBD (0.50%) is worse than 68.29% of its industry peers.
In the last couple of years the Operating Margin of CBD has declined.
Looking at the Gross Margin, with a value of 25.02%, CBD is in the better half of the industry, outperforming 63.41% of the companies in the same industry.
In the last couple of years the Gross Margin of CBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.5% | ||
| PM (TTM) | N/A | ||
| GM | 25.02% |
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
CBD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
CBD has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CBD has been increased compared to 5 years ago.
Compared to 1 year ago, CBD has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.07, we must say that CBD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.07, CBD is doing worse than 73.17% of the companies in the same industry.
A Debt/Equity ratio of 1.72 is on the high side and indicates that CBD has dependencies on debt financing.
With a Debt to Equity ratio value of 1.72, CBD is not doing good in the industry: 82.93% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.07 |
ROIC/WACC0.09
WACC5.48%
2.3 Liquidity
CBD has a Current Ratio of 1.21. This is a normal value and indicates that CBD is financially healthy and should not expect problems in meeting its short term obligations.
CBD has a Current ratio of 1.21. This is comparable to the rest of the industry: CBD outperforms 51.22% of its industry peers.
CBD has a Quick Ratio of 1.21. This is a bad value and indicates that CBD is not financially healthy enough and could expect problems in meeting its short term obligations.
CBD has a better Quick ratio (0.89) than 70.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The earnings per share for CBD have decreased strongly by -1171.43% in the last year.
The Revenue for CBD has decreased by -59.86% in the past year. This is quite bad
CBD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.17% yearly.
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q72.55%
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Revenue growth Q2Q-69.65%
3.2 Future
The Earnings Per Share is expected to grow by 24.83% on average over the next years. This is a very strong growth
CBD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.97% yearly.
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CBD is valued cheaply inside the industry as 87.80% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 5 |
4.3 Compensation for Growth
A more expensive valuation may be justified as CBD's earnings are expected to grow with 24.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3Y24.83%
5. Dividend
5.1 Amount
CBD has a Yearly Dividend Yield of 13.41%, which is a nice return.
In the last 3 months the price of CBD has falen by -47.63%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
CBD's Dividend Yield is rather good when compared to the industry average which is at 3.08. CBD pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.45, CBD pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.41% |
5.2 History
The dividend of CBD decreases each year by -24.04%.
CBD has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-24.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
CBD has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-4.93%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
CIA BRASILEIRA DE DIS- ADR
NYSE:CBD (4/18/2024, 7:04:00 PM)
After market: 0.4357 -0.01 (-2.09%)0.445
-0.01 (-3.05%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap218.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.41% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.3% | ||
| ROE | -48.12% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 0.5% | ||
| PM (TTM) | N/A | ||
| GM | 25.02% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y83.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y